Business Context and Reporting Period
Company: Kimberly-Clark Corporation
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2008
Reporting Status: Large accelerated filer; Unaudited financial statements.
Outstanding Shares: 413,759,859 shares as of October 31, 2008.
Key Financial Metrics
| Metric (Millions, except per share) | 3 Months Ended Sep 30, 2008 | 9 Months Ended Sep 30, 2008 |
|---|---|---|
| Net Sales | $4,998.2 | $14,817.1 |
| Operating Profit | $609.5 | $1,923.7 |
| Net Income | $413.1 | $1,270.7 |
| Diluted EPS | $0.99 | $3.03 |
| Cash Provided by Operations | $640.9 (Q3 only) | $1,837.8 (YTD) |
| Cash and Cash Equivalents | $524.1 (Sep 30, 2008) | - |
| Total Debt (Short + Long Term) | $6,240.4 (Sep 30, 2008) | - |
Note: Total Debt calculated as Debt payable within one year ($1,870.9M) + Long-Term Debt ($4,369.5M).
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 8.2% in Q3 2008 and 9.7% YTD compared to 2007. Growth was driven by higher net selling prices (approx. 4% Q3, 3% YTD) and favorable currency effects, partially offset by volume declines in Consumer Tissue.
- Profitability Decline: Operating profit decreased 10.7% in Q3 and 1.2% YTD. Net income fell 8.8% in Q3 and 7.0% YTD.
- Cost Inflation: Significant cost inflation impacted results, totaling $250 million in Q3 (an all-time high), driven by raw materials (polymers, fiber), energy, and distribution costs.
- Segment Performance:
- Personal Care: Sales up 11.7% (Q3); Operating profit up 2.0%.
- Consumer Tissue: Sales up 5.0% (Q3); Operating profit down 20.0% due to volume declines and cost inflation.
- Health Care: Sales up 3.7% (Q3); Operating profit down 49.5% due to raw material inflation and lower prices.
- Accounting Change: The company consolidated two financing entities on June 30, 2008, resulting in a $7.7 million after-tax extraordinary loss recorded in the second quarter.
Guidance, Outlook, and Risks
- Outlook: Management targets continued solid organic sales growth for the remainder of 2008, driven by price and mix. Volume growth is expected to be weak due to economic conditions and a focus on revenue realization.
- Q4 Expectations: Operating profit is expected to improve sequentially in Q4 due to price increases and commodity cost reductions. However, currency fluctuations are now expected to have a negative impact of more than 10 cents per share on Q4 results.
- Capital Allocation:
- Share Repurchases: Full-year target reduced to $600–$650 million (from $700–$800 million). Approximately $550 million spent YTD.
- Capital Spending: Expected to range between $850–$950 million for 2008.
- Dividends: Cash dividends declared were $0.58 per share for Q3.
- Risks & Contingencies:
- Cost Volatility: Ongoing exposure to raw material, energy, and distribution cost inflation.
- Currency: Significant adverse impact from strengthening U.S. dollar against key currencies (AUD, BRL, GBP, KRW).
- Legal: Ongoing dispute with Delcora regarding wastewater discharge fees; management does not expect a material adverse effect.
- Strategic Cost Reduction: Plan expected to incur cumulative pretax charges of $880–$900 million by year-end. Approximately $875 million incurred to date.
Investor Verification Checklist
- Cost Inflation Impact: Verify the sustainability of the $250 million cost inflation run rate and the timeline for realizing commodity cost reductions (estimated up to 6 months).
- Currency Exposure: Assess the magnitude of the projected >$0.10 per share negative currency impact on Q4 earnings.
- Volume Trends: Monitor Consumer Tissue volume declines in North America and Europe to determine if price increases are successfully offsetting demand erosion.
- Debt Structure: Review the $617 million in monetization loans consolidated in Q2 and their maturity dates (2009) to assess refinancing risk.
- Strategic Plan Completion: Confirm the final costs of the strategic cost reduction plan against the $880–$900 million estimate as the program concludes in December 2008.